Henry Schein CEO Stanley Bergman discusses the future of American health care and Trump’s Medicare plan.
The drug company Biogen Inc. says it will seek federal approval for a medicine to treat early Alzheimer’s disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia.
Continue Reading Below
The announcement Tuesday is a surprise because the company earlier this year stopped two studies of the drug when partial results suggested it was not working. The company now says a new analysis of more results suggest that the drug helped reduce a decline of thinking skills at the highest dose.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
The drug, called aducanumab, aims to help the body clear harmful plaques from the brain. Cambridge, Massachusetts-based Biogen is developing it with a Japanese company, Eisai Co. Ltd.
Shares of Biogen soared 36% to $305 in pre-market trading Tuesday.
